

SUPPLEMENTARY MATERIALS

EFFECTS OF *GSTT1* GENOTYPE ON DETOXIFICATION OF 1,3-BUTADIENE DERIVED DIEPOXIDE AND FORMATION OF PROMUTAGENIC DNA-DNA CROSSLINKS IN HUMAN HAPMAP CELL LINES

Gunnar Boysen,^{†,‡,§,£} Rashi Arora,^{¶,£} Amanda Degner,^{†,¶} Karin R Vevang,[€]
Christopher Chao,[†] Freddy Rodriguez,[†] Scott J. Walmsley,^{¶,¢} Luke Erber,[†]
Natalia Y. Tretyakova,^{†,¶,*} and Lisa A. Peterson^{¶,€,*}

[†] Department of Medicinal Chemistry, University of Minnesota Minneapolis, MN 55455,

[‡] Department of Environmental and Occupational Health, University of Arkansas for Medical Sciences, Little Rock, AR 72205

[§] The Winthrop P Rockefeller Cancer Institute University of Arkansas for Medical Sciences, Little Rock, AR 72205

[¶] University of Minnesota Masonic Cancer Center, Minneapolis, MN 55455

[€] Division of Environmental Health Sciences, University of Minnesota, Minneapolis, MN 55455


[¢] Institute for Health Informatics, University of Minnesota, Minneapolis, MN 55455

[£] These two authors contributed equally

* Corresponding authors:

Lisa Peterson: Masonic Cancer Center, University of Minnesota, 2231 6th Street SE, 2-126 CCRB, Minneapolis, MN 55455, USA; 612-626-0164; peter431@umn.edu

Natalia Tretyakova: Masonic Cancer Center, University of Minnesota, 2231 6th Street SE, 2-147 CCRB, Minneapolis, MN 55455, USA; 612-626-3432; trey001@umn.edu






Figure S2. ¹H-NMR spectrum of *S*-(1,2,3-trihydroxybutyl)-GSH (THB-GSH) prepared from L-glutathione and racemic DEB as a mixture of diastereomers. The NMR spectra was acquired in D₂O at ambient temperature using a Bruker (600.64 MHz) Avance Neo spectrometer equipped with a 5 mm TCI cryoprobe at the Minnesota NMR Center and Bruker zg30 pulse program with a sweep width of 11,904.76 Hz, 65536 data points, 128 scans, recycle delay of 1.0 sec, and 32 receiver gain.




Figure S3. ^1H - ^{13}C HSQC spectrum of *S*-(1,2,3-trihydroxybutyl)-GSH (THB-GSH) prepared from L-glutathione and racemic DEB as a mixture of diastereomers. The NMR spectra was acquired in D_2O at ambient temperature using a Bruker (600.64 MHz) Avance Neo spectrometer equipped with a 5 mm TCI cryoprobe at the Minnesota NMR Center and Bruker hsqcedetgpsisp2.3 pulse program with 4096 x 128 data matrix, 32 dummy scans, 16 scans, recycle delay of 1.0 sec, and 101 receiver gain.




Figure S4. Proposed MS fragments for (A) HEB-GSH and (B) [$^{15}\text{N}^{13}\text{C}_2$ -glycine]HEB-GSH.




Figure S5. A representative immunoblot of GSTT1 protein (Sigma GSTT1 Antibody: ABS1653) and loading control, Vinculin (Sigma Vinculin antibody: SAB1404522) using HapMap cell lysates and controls.




Figure S6. Representative flow cytometry plots using annexin V, allophycocyanin (APC) and propidium iodide (PI) staining for apoptosis measurement. During early apoptotic stage, cells stain with annexin V but still exclude PI. In later stages of apoptosis, cells stain with both APC and PI. Together, early and late apoptotic cells sum up to give total apoptosis induced in the population.




Figure S7. Representative flow cytometry plots for micronuclei formation measurement (cell line: GM12812). A liberal “Light Scatter” region is drawn as MN could have got excluded otherwise based on their small size. These events are further gated to exclude EMA positive events, denoting chromatin from dead/dying cells. Only the “not EMA” events are further gated to determine MN frequency.




Figure S8. Cytotoxicity curves for sixteen lymphocyte cell lines. Lymphocyte cell lines were seeded (2,000 cells per well) in triplicate in 96-well plates (final volume:100 μ L). After 24 h, the cells were treated with 0 - 50 μ M DEB for 72 h. Cell viability was determined with CellTiter Glo (Promega, Madison, WI) according to the manufacturer's instructions. Cell survival was normalized to the luminescence of the cells treated with 0 μ M. Standard deviation for replicate analysis were <20%; error bars are omitted for clarity.

Table S1. GSTT1 and GSTM1 copy number in the cell lines.¹

Cell line	GSTT1	GSTM1
GM10861	0	0
GM10851	0	0
GM18872	0	2
GM18870	0	1
GM19139	0	1
GM18508	0	0
GM12874	0	0
GM18912	0	1
GM18517	0	2
GM19128	0	1
GM19211	1	0
GM12812	1	0
GM19200	2	2
GM12145	1	0
GM18516	1	1
GM12155	2	0
GM10860	1	0
GM19130	2	2

¹As reported in *Nat. Genet.* 38, 86-92, 2006.

Table S2. Apoptosis measurements in DEB-treated <i>GSTT1</i> null HapMap cell lines. ¹					
Cell line	GSTT1 Genotype	μM DEB	Early apoptosis (AnnexinV+/PI-)	Late apoptosis (AnnexinV+/PI+)	Total apoptosis (Early+Late)
GM10861	-/-	0	0.4% ± 0.07%	0.4% ± 0.04%	0.8% ± 0.03%
		5	1.2% ± 0.09%	0.7% ± 0.04%	1.8% ± 0.1%
		10	1.2% ± 0.2%	0.8% ± 0.07%	2.0% ± 0.1%
GM10851	-/-	0	0.5% ± 0.08%	0.2% ± 0.02%	0.7% ± 0.1%
		5	1.3% ± 0.07%	0.3% ± 0.05%	1.6% ± 0.08%
		10	2.0% ± 0.2%	0.5% ± 0.1%	2.6% ± 0.1%
GM18872	-/-	0	1.3% ± 0.1%	0.4% ± 0.06%	1.8% ± 0.2%
		5	2.1% ± 0.09%	0.8% ± 0.01%	2.9% ± 0.09%
		10	4.1% ± 0.2%	1.7% ± 0.2%	5.8% ± 0.4%
GM18870	-/-	0	1.6% ± 0.08%	1.0% ± 0.06%	2.5% ± 0.08%
		5	4.8% ± 0.2%	2.6% ± 0.2%	7.4% ± 0.3%
		10	6.1% ± 0.1%	5.5% ± 0.3%	11.6% ± 0.4%
GM19139	-/-	0	1.0% ± 0.4%	1.5% ± 0.7%	2.5% ± 0.6%
		5	4.5% ± 1.8%	3.1% ± 2.2%	7.6% ± 3.9%
		10	5.9% ± 1.9%	5.9% ± 1.7%	11.7% ± 1.1%
GM18508	-/-	0	0.5% ± 0.2%	0.9% ± 0.8%	1.4% ± 0.8%
		5	5.7% ± 0.1%	3.0% ± 0.09%	8.7% ± 0.07%
		10	6.8% ± 2.3%	6.5% ± 3.7%	13.3% ± 4.1%
GM12874	-/-	0	1.3% ± 0.2%	0.8% ± 0.4%	2.1% ± 0.5%
		5	8.1% ± 0.9%	6.4% ± 1.6%	14.5% ± 2.6%
		10	8.6% ± 0.8%	7.1% ± 4.8%	15.7% ± 5.1%
GM18912	-/-	0	1.7% ± 0.3%	0.6% ± 0.03%	2.4% ± 0.3%
		5	14.6% ± 0.6%	7.5% ± 3.4%	22.1% ± 3.9%
		10	15.7% ± 1.3%	11.8% ± 4.9%	27.5% ± 6.1%
GM18517	-/-	0	1.0% ± 0.2%	0.3% ± 0.1%	1.3% ± 0.1%
		5	14.3% ± 2.6%	12.6% ± 2.9%	26.9% ± 5.4%
		10	13.2% ± 3.0%	17.4% ± 0.4%	30.6% ± 3.2%
GM19128	-/-	0	2.0% ± 0.9%	1.0% ± 0.3%	3.0% ± 0.6%
		5	17.5% ± 3.4%	10.4% ± 2.6%	27.9% ± 6.0%
		10	19.7% ± 2.1%	19.0% ± 2.1%	38.8% ± 4.2%

¹Lymphoblastoid cell lines were treated with 0, 5 or 10 μM DEB for 24 h in triplicate. See The percent of apoptotic cells was determined based on annexin V marker expression on the cell surface as detected by allophycocyanin (APC) labeled annexin-V. During early apoptotic stage, cells stain with APC but still exclude propidium iodide (PI), whereas cells in later stages of apoptosis stain with both APC and PI. Together early and late apoptotic cells sum up to give total apoptosis induced in the population.

Table S3. Apoptosis measurement in DEB-treated *GSTT1* Positive HapMap cell lines.¹

Cell line	GSTT1 Genotype	μM DEB	Early apoptosis (AnnexinV+/PI-)	Late apoptosis (AnnexinV+/PI+)	Total apoptosis (Early+Late)
GM19211	-/+	0	0.8% ± 0.06%	0.3% ± 0.01%	1.1% ± 0.06%
		5	1.6% ± 0.1%	0.4% ± 0.05%	2.1% ± 0.2%
		10	2.0% ± 0.2%	0.5% ± 0.1%	2.6% ± 0.2%
GM12812	-/+	0	1.0% ± 0.07%	0.3% ± 0.02%	1.4% ± 0.05%
		5	1.5% ± 0.09%	0.7% ± 0.03%	2.2% ± 0.1%
		10	2.5% ± 0.9%	1.1% ± 0.4%	3.7% ± 1.3%
GM12145	-/+	0	1.4% ± 1.4%	1.3% ± 0.9%	2.8% ± 0.8%
		5	5.1% ± 0.6%	3.3% ± 0.7%	8.4% ± 1.2%
		10	4.1% ± 2.2%	4.2% ± 1.7%	8.3% ± 3.7%
GM18516	-/+	0	1.2% ± 0.1%	0.4% ± 0.03%	1.6% ± 0.09%
		5	4.2% ± 0.1%	1.2% ± 0.2%	5.4% ± 0.3%
		10	6.5% ± 0.1%	1.7% ± 0.01%	8.2% ± 0.1%
GM10860	-/+	0	2.3% ± 0.2%	1.5% ± 0.1%	3.8% ± 0.2%
		5	4.7% ± 0.2%	2.6% ± 0.4%	7.4% ± 0.4%
		10	6.0% ± 0.3%	4.1% ± 0.3%	10.1% ± 0.5%
GM19200	+/+	0	0.7% ± 0.4%	0.7% ± 0.3%	1.4% ± 0.2%
		5	2.6% ± 0.1%	0.8% ± 0.04%	3.4% ± 0.1%
		10	2.6% ± 0.6%	2.4% ± 1.4%	5.1% ± 0.9%
GM12155	+/+	0	0.8% ± 0.2%	0.6% ± 0.3%	1.4% ± 0.3%
		5	4.2% ± 1.3%	3.3% ± 1.2%	7.5% ± 2.5%
		10	5.5% ± 2.4%	3.2% ± 2.0%	8.6% ± 4.2%
GM19130	+/+	0	1.1% ± 0.4%	0.7% ± 0.7%	1.8% ± 0.4%
		5	5.3% ± 0.5%	3.3% ± 0.8%	8.6% ± 1.0%
		10	7.7% ± 0.9%	4.1% ± 1.2%	11.8% ± 1.1%

¹Lymphoblastoid cell lines were treated with 0, 5 or 10 μM DEB for 24 h in triplicate. The percent of apoptotic cells was determined based on annexin V marker expression on the cell surface as detected by allophycocyanin (APC) labeled annexin-V. During early apoptotic stage, cells stain with APC but still exclude propidium iodide (PI), whereas cells in later stages of apoptosis stain with both APC and PI. Together early and late apoptotic cells sum up to give total apoptosis induced in the population.

Table S4. Average extent of apoptosis in <i>GSTT1</i> negative and positive cell lines based on <i>GSTT1</i> genotype. ¹				
GSTT1 genotype	μM DEB	Early apoptosis (Annexin V+/PI-)	Late apoptosis (Annexin V+/PI+)	Total apoptosis (Early+Late)
-/-	0	1.1% ± 0.5%	0.7% ± 0.4%	1.8% ± 0.8%
	5	7.4% ± 6.0%	4.7% ± 4.3%	12% ± 10%
	10	8.3% ± 6.1%	7.3% ± 6.5%	16% ± 12%
-/+	0	1.4% ± 0.6%	0.8% ± 0.6%	2.2% ± 1.2%
	5	3.4% ± 1.7%	1.6% ± 1.3%	5.1% ± 2.9%
	10	4.2% ± 2.0%	2.3% ± 1.7%	6.5% ± 3.2%
+/+	0	0.9% ± 0.1%	0.9% ± 0.6%	1.8% ± 0.6%
	5	3.3% ± 1.5%	2.0% ± 1.2%	5.2% ± 2.6%
	10	4.1% ± 2.4%	3.1% ± 1.3%	7.3% ± 3.3%

¹Values represent mean ± SD. PI = propidium iodide.

Table S5. Univariate responses of apoptosis, MN, DEB-GSH formation or between *GSTT* positive and *GSTT* negative (*GSTT*^{+/-}) cell lines, *GSTM1* genotypes and between DEB treatment levels.¹

ANOVA		SS	F	df	P(>F)
Apoptosis	Treatment	0.099	10.583	2	< 0.001
	<i>GSTT1</i>	0.036	7.767	1	0.008
	<i>GSTM1</i>	0.014	2.9491	1	0.093
MN	Treatment	0.002	12.194	2	< 0.001
	<i>GSTT1</i>	0.000	2.321	1	0.135
	<i>GSTM1</i>	0.000	0.601	1	0.442
DEB-GSH	<i>GSTT1</i>	0.006	20.121	1	<0.001
	<i>GSTM1</i>	0.002	5.245	1	0.037 ²
bis-N7G-BD	<i>GSTT1</i>	0.054	0.169	1	0.687
	<i>GSTM1</i>	0.057	0.679	1	0.679

¹The significance of the change in apoptosis and MN for *GSTT1* and *GSTM1* genotypes were measured using Analysis of Variance using the model: *apoptosis*~ *GSTT1* **treatment***GSTM1* or *MN*~ *GSTT1* **treatment***GSTM1*, DEB-GSH (5uM DEB treatment) ~*GSTT1***GSTM1*, or *bis-N7G-BD* (5 μM DEB treatment)~*GSTT1***GSTM1*. (SS) sum of squares, (F) F test, (df) degrees of freedom, (P(>F)) p level. For the genotype analyses, heterozygotes and homozygote were pooled and compared to GST negatives.

²The average level of DEB-GSH in *GSTM1* negative cells is 298 ± 165 fmol/mg protein and average level of DEB-GSH *GSTM1* positive cells is 171 ± 161 fmol/mg protein.